EMA
approval
· 2014-09-26
Ketoconazole HRA recommended for approval in Cushing's syndrome
Summary
The EMA recommends granting marketing authorization for ketoconazole hydrochloride (HRA) for the treatment of Cushing's syndrome, based on its potential to cont…
Upgrade for the full analysis, importance score, and drug timeline.